A Phase 3 interventional study of Secukinumab in Juvenile Psoriatic Arthritis and Enthesitis Related Arthritis, sponsored by Novartis Pharmaceuticals. Completed at 23 sites in 9 countries. Open to participants aged 2 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-10-16.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Arthritis, Juvenile by Novartis — 6 open to participants now, 6 under way, none of them phase 3. Arthritis, Juvenile · Novartis.
Among the 18 studies in Arthritis, Juvenile by Novartis, this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2019, is one of 9 in phase 3, and was the 10th registered.
366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.
Browse Arthritis, Juvenile studies →6 of the 18 studies in Arthritis, Juvenile by Novartis are open now, in 10 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Switzerland
Ages 1+
Novartis Pharmaceuticals · Sites in Korea, Republic of
Ages 6–100
Novartis Pharmaceuticals · Sites in United States, Canada, France and 5 more countries
Ages 1+
Novartis Pharmaceuticals · Sites in United States
Ages 2–17
Novartis Pharmaceuticals · Sites in Korea, Republic of
Ages 2–100
By country, each count listing its studies:
Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.
This study: 2 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 9
First in 2006; this study’s year is marked. 1 started in 2019.
This study's enrollment of 55 is close to the median of 52 across 231 interventional studies indexed under Arthritis, Juvenile.
Median enrollment 43 across the 12 interventional studies, 76 across the 5 observational. Of the 9 that completed or were terminated, 8 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
3 of the studies in Arthritis, Juvenile by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07517250Novartis PharmaceuticalsA Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients | 2026-12-03 |
| NCT07203001Novartis PharmaceuticalsA Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease | 2027-04-22 |
| NCT07243782Novartis PharmaceuticalsRegulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea | 2027-06-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 18 studies in Arthritis, Juvenile by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Optional open label, roll over extension study to investigate the efficacy and safety of secukinumab treatment in Juvenile Idiopathic Arthritis (JIA) subtypes of Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA).
This study is an extension of a previous core study (NCT03031782 [CAIN457F2304]) aiming to assess the long-term efficacy, safety, and tolerability of secukinumab treatment in patients who completed the core study and chose to participate in the extension study. The primary objective was to gather comprehensive data on the efficacy and safety of secukinumab over an extended period.
At Week 104 of the core study, all eligible patients could opt to roll over to the extension study and continue receiving secukinumab at either 75 mg or 150 mg, as they were at the Week 100 visit of the core study. The treatment involved subcutaneous injections using pre-filled syringes (PFS). The duration of patient participation could range from a minimum of one year to a maximum of four years, or until one of the following conditions was met: the drug was locally approved, marketed, and reimbursed, secukinumab could be provided free of charge to patients in compliance with local guidelines, or a maximum of 4 years study duration.
During the extension study (starting from Week 108), to maintain a high proportion of clinically meaningful response during the entire duration of the extension study, the dosing options available, at the Investigator's discretion, were as follows:
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants initially received secukinumab 75mg subcutaneously once every four weeks in the extension study. If the signs and symptoms of the participants were not adequately controlled with the 75mg dose, as determined by the investigator, the dose could be escalated to 150mg subcutaneously. For patients weighing 50kg and over, the dose could further be escalated to 300mg subcutaneously every four weeks. The dose escalation from secukinumab 75mg subcutaneously to 300mg subcutaneously was to be implemented in two steps, with the first step being an increase to 150mg subcutaneously, followed by another escalation to 300mg subcutaneously, based on the judgement of the investigator.
Drug: Secukinumab
Participants initially received secukinumab 150mg subcutaneously once every four weeks in the extension study. If the signs and symptoms of the participants were not adequately controlled with the 150mg dose, as determined by the investigator, the dose could be escalated to 300mg subcutaneously.
Drug: Secukinumab
Secukinumab solution for subcutaneous injections was provided in PFS. Initially, participants continued to receive secukinumab at either 75 mg (in 0.5mL) or 150 mg (in 1mL) every 4 weeks, consistent with their dosage at the Week 100 visit of the core study. The dose could be escalated from 75 mg to 150 mg for patients whose signs and symptoms were not fully controlled, as judged by the investigator, with the current 75 mg dose. Furthermore, the dose could also be escalated to 300 mg every 4 weeks for patients weighing 50kg and over who were currently on the 150 mg dose and whose signs and symptoms were not well-controlled, as judged by the investigator. The dose escalation from secukinumab 75 mg to 300 mg was to be implemented in two steps (first 150 mg and then 300 mg based on the investigator's judgment). At each study treatment time point, one or two subcutaneous injections in the form of PFS were administered.
Also known as: AIN457
Percentage of Participants With Juvenile Idiopathic Arthritis American College of Rheumatology (JIA ACR) 30 Response
The JIA ACR response criteria consisted of 6 core criteria: * Physician global assessment of disease activity on a 0-100 mm VAS (0=very good and 100=very poor). * Parent's or patients' global assessment of overall well-being on a 0-100 mm VAS (0=very well and 100=very poor). * Functional ability (CHAQ: Childhood Health Assessment Questionnaire): 30 questions across 8 domains assessing the child's functional abilities. The total score was calculated as the average of the scores for each domain. It ranged from 0 (no disability) to 3 (very severe disability). * Number of joints with active arthritis (as per ACR definition), ranging from 0 to 73. * Number of joints with limited range of motion, ranging from 0 to 69. * Index of inflammation: C-reactive Protein (CRP) levels The JIA ACR 30 response was achieved if 3 of any 6 core set variables improved by at least 30% from baseline of the core study, and no more than 1 variable worsening more than 30%
Time frame: Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.
Percentage of Participants With JIA ACR 50 Response
The JIA ACR response criteria consisted of 6 core criteria: * Physician global assessment of disease activity on a 0-100 mm VAS (0=very good and 100=very poor). * Parent's or patients' global assessment of overall well-being on a 0-100 mm VAS (0=very well and 100=very poor). * Functional ability (CHAQ): 30 questions across 8 domains assessing the child's functional abilities. The total score was calculated as the average of the scores for each domain (0 \[no disability\] to 3 \[very severe disability\]). * Number of joints with active arthritis (as per ACR definition), ranging from 0 to 73. * Number of joints with limited range of motion, ranging from 0 to 69. * Index of inflammation: CRP levels The JIA ACR 50 responses were achieved if 3 of any 6 core set variables improved by at least 50% from baseline of the core study, and no more than 1 variable worsening \> 30%
Time frame: Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.
Percentage of Participants With JIA ACR 70 Response
The JIA ACR response criteria consisted of 6 core criteria: * Physician global assessment of disease activity on a 0-100 mm VAS (0=very good and 100=very poor). * Parent's or patients' global assessment of overall well-being on a 0-100 mm VAS (0=very well and 100=very poor). * Functional ability (CHAQ): 30 questions across 8 domains assessing the child's functional abilities. The total score was calculated as the average of the scores for each domain (0 \[no disability\] to 3 \[very severe disability\]). * Number of joints with active arthritis (as per ACR definition), ranging from 0 to 73. * Number of joints with limited range of motion, ranging from 0 to 69. * Index of inflammation: CRP levels The JIA ACR 70 responses were achieved if 3 of any 6 core set variables improved by at least 70%, from baseline of the core study, and no more than 1 variable worsening \> 30%
Time frame: Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.
Percentage of Participants With JIA ACR 90 Response
The JIA ACR response criteria consisted of 6 core criteria: * Physician global assessment of disease activity on a 0-100 mm VAS (0=very good and 100=very poor). * Parent's or patients' global assessment of overall well-being on a 0-100 mm VAS (0=very well and 100=very poor). * Functional ability (CHAQ): 30 questions across 8 domains assessing the child's functional abilities. The total score was calculated as the average of the scores for each domain (0 \[no disability\] to 3 \[very severe disability\]). * Number of joints with active arthritis (as per ACR definition), ranging from 0 to 73. * Number of joints with limited range of motion, ranging from 0 to 69. * Index of inflammation: CRP levels The JIA ACR 90 responses were achieved if 3 of any 6 core set variables improved by at least 90% from baseline of the core study, and no more than 1 variable worsening \> 30%
Time frame: Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.
Percentage of Participants With JIA ACR 100 Response
The JIA ACR response criteria consisted of 6 core criteria: * Physician global assessment of disease activity on a 0-100 mm VAS (0=very good and 100=very poor). * Parent's or patients' global assessment of overall well-being on a 0-100 mm VAS (0=very well and 100=very poor). * Functional ability (CHAQ): 30 questions across 8 domains assessing the child's functional abilities. The total score was calculated as the average of the scores for each domain (0 \[no disability\] to 3 \[very severe disability\]). * Number of joints with active arthritis (as per ACR definition), ranging from 0 to 73. * Number of joints with limited range of motion, ranging from 0 to 69. * Index of inflammation: CRP levels The JIA ACR 100 responses were achieved if 3 of any 6 core set variables improved with 100% from baseline of the core study, and no more than 1 variable worsening \> 30%
Time frame: Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.
Number of Participants With Inactive Disease Status
Inactive disease status was confirmed in a patient when all the following conditions were met: * No joints with active arthritis * No uveitis * CRP value within normal limits for the laboratory where tested or, if elevated, not attributable to JIA * Physician's global assessment of disease activity score ≤ 10mm * Duration of morning stiffness attributable to JIA lasting ≥15 minutes.
Time frame: Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.
Change From Baseline of Core Study CAIN457F2304 in JIA ACR Core Component - Physician Global Assessment of Disease Activity
The JIA ACR response criteria consisted of 6 core criteria, one of which was the physician global assessment of disease activity. this assessment was conducted using a 100 mm VAS score, where 0 represented the best disease activity and 100 the worst. The change from baseline of the core study of the physician global assessment of disease activity was measured, with a negative change indicating improvement.
Time frame: Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.
Change From Baseline of Core Study CAIN457F2304 in JIA ACR Core Component - Parent's or Patients' Global Assessment of Overall Well-being
The JIA ACR response criteria included six core components, one of which was the parent's or patients' global assessment of overall well-being. This assessment was conducted using a 100 mm VAS score, where 0 represented "very well" and 100 "very poor". The change from baseline of the core study in the parent's or patients' global assessment of overall well-being was measured, with a negative change indicating improvement
Time frame: Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.
Change From Baseline of Core Study CAIN457F2304 in JIA ACR Core Component - Functional Ability (CHAQ)
The JIA ACR response criteria included six core components, one of which was the functional ability, measured by the CHAQ. The CHAQ questionnaire consisted of 30 questions across 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Each domain was scored on a 4-point scale, and the total score was calculated as the average of the scores for each domain. The total score ranged from 0 (no disability) to 3 (very severe disability). The change from baseline of the core study in the CHAQ was measured, with a negative change indicating improvement.
Time frame: Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.
Change From Baseline of Core Study CAIN457F2304 in JIA ACR Core Component - Number of Joints With Active Arthritis
The JIA ACR response criteria included six core components, one of which was the number of joints with active arthritis. This was determined using the ACR definition, which identifies active arthritis as any joint with swelling or, in the absence of swelling, limitation of motion accompanied by either pain on motion or tenderness not due to deformity. The active joint count ranged from 0 to 73. The change from baseline of the core study in the number of active joints was measured, with a negative change indicating improvement.
Time frame: Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.
Change From Baseline of Core Study CAIN457F2304 in JIA ACR Core Component - Number of Joints With Limited Range of Motion
The JIA ACR response criteria included six core components, one of which was the number of joints with limited range of motion. A total of 69 joints were assessed for limitation of motion. The change from baseline of the core study in the number of joints with limited range of motion was measured, with a negative change indicating improvement.
Time frame: Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.
Change From Baseline of Core Study CAIN457F2304 in JIA ACR Core Component - CRP Levels
The JIA ACR response criteria included six core components, one of which was CRP levels, an inflammation biomarker. Serum concentrations of CRP were determined, and the change from baseline of the core study was assessed, with negative changes indicating improvement.
Time frame: Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.
Change From Baseline of Core Study CAIN457F2304 of 27-joint Juvenile Arthritis Disease Activity Score (JADAS-27)
The JADAS-27 was used for assessment of disease activity, and it included 4 measures: * Physician global assessment of disease activity (VAS range: 0 to 10; where 0=very good and 100=very poor) * Parent/participant global assessment of well-being (VAS range: 0 to 10; 0=very well and 100=very poor) * Count of joints with active disease (range: 0 to 27; where 0= no disease activity and 27= maximum disease activity) * Index of inflammation determined by CRP concentration, calculated as: (CRP (mg/l) -10)/10. Before calculation, CRP values \<10 mg/l were converted to 10 and CRP values \>110 mg/l were converted to 110. The normalized scale ranged from 0 to 10; where 0= no disease activity and 10= maximum disease activity. JADAS-27 score was calculated as the sum of the score of its 4 components, ranging from 0 to 57 where 0= no disease activity and 57= maximum disease activity. The change from baseline of the core study was assessed. A negative change from baseline indicated improvement.
Time frame: Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.
Change From Baseline of Core Study CAIN457F2304 of 71-joint Juvenile Arthritis Disease Activity Score (JADAS-71)
The JADAS-27 was used for assessment of disease activity, and it included 4 measures: * Physician global assessment of disease activity (VAS range: 0 to 10; where 0=very good and 100=very poor) * Parent/participant global assessment of well-being (VAS range: 0 to 10; 0=very well and 100=very poor) * Count of joints with active disease (range: 0 to 71; where 0= no disease activity and 71= maximum disease activity) * Index of inflammation determined by CRP concentration, calculated as: (CRP (mg/l) -10)/10. Before calculation, CRP values \<10 mg/l were converted to 10 and CRP values \>110 mg/l were converted to 110. The normalized scale ranged from 0 to 10; where 0= no disease activity and 10= maximum disease activity. JADAS-27 score was calculated as the sum of the score of its 4 components, ranging from 0 to 101 where 0= no disease activity and 101= maximum disease activity. The change from baseline of the core study was assessed. A negative change from baseline indicated improvement.
Time frame: Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.
Change From Baseline of Core Study CAIN457F2304 in Total Enthesitis Count
The following 16 entheseal sites were assessed for the presence or absence of tenderness (enthesitis) on each side of the body: * Anterior Entheses: Greater trochanter of the Femur; Medial condyle of the femur; Lateral condyle of the femur * Posterior Entheses: Greater tuberosity of humerus; medial epicondyle of humerus; lateral epicondyle of humerus, Achilles tendon; and calcaneal insertion of the plantar fascia. Tenderness on examination was recorded as either present (1) or absent (0) for each of the 16 sites, The total enthesitis count ranged from 0 to 16. The change from baseline of the core study was assessed. A negative change from baseline indicated improvement
Time frame: Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.
Change From Baseline of Core Study CAIN457F2304 in Total Dactylitis Count
The dactylitis count was the number of fingers and toes presenting with swelling and inflammation. Swelling and inflammation on examination was recorded as either present (1) or absent (0) for each of the 20 sites, The total dactylitis count ranged from 0 to 20. The change from baseline of the core study was assessed. A negative change from baseline indicated improvement
Time frame: Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.
Serum Concentrations of Secukinumab Over Time
Serum concentration of secukinumab over time. Blood samples for pharmacokinetics were taken pre-dose at the scheduled time points.
Time frame: Pre-dose at Week 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.
Number of Participants With Treatment-emergent Anti-Drug Antibodies (ADAs) of Secukinumab
Number of participants with treatment-emergent Anti-Drug Antibodies (ADAs) of secukinumab. Blood samples were collected for immunogenicity (anti-AIN457 antibodies) assessments.
Time frame: From baseline of the core study up to Week 312. Study week is defined with respect to the core study.
Participants were recruited in 24 centers across 9 countries
| Milestone | Group 1- Secukinumab 75 mg | Group 2 - Secukinumab 150 mg |
|---|---|---|
| Started | 19 | 36 |
| Secukinumab escalated to 150 mg | 6 | 0 |
| Secukinumab escalated to 300 mg | 2 | 14 |
| Treated | 19 | 35 |
| Completed | 10 | 12 |
| Not completed | 9 | 24 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Lack of efficacy | 2 | 4 |
| Withdrew: Post study access to treatment | 3 | 11 |
| Withdrew: Physician decision | 1 | 4 |
| Withdrew: Subject decision | 2 | 4 |
| Withdrew: Guardian decision | 1 | 0 |
The JIA ACR response criteria consisted of 6 core criteria: * Physician global assessment of disease activity on a 0-100 mm VAS (0=very good and 100=very poor). * Parent's or patients' global assessment of overall well-being on a 0-100 mm VAS (0=very well and 100=very poor). * Functional ability (CHAQ: Childhood Health Assessment Questionnaire): 30 questions across 8 domains assessing the child's functional abilities. The total score was calculated as the average of the scores for each domain. It ranged from 0 (no disability) to 3 (very severe disability). * Number of joints with active arthritis (as per ACR definition), ranging from 0 to 73. * Number of joints with limited range of motion, ranging from 0 to 69. * Index of inflammation: C-reactive Protein (CRP) levels The JIA ACR 30 response was achieved if 3 of any 6 core set variables improved by at least 30% from baseline of the core study, and no more than 1 variable worsening more than 30%
| Percentage of Participants | Group 1- Secukinumab 75 mg | Group 2 - Secukinumab 150 mg | Total Secukinumab Dose |
|---|---|---|---|
| Week 104 | 100 (79.1 to 100) | 100 (87.7 to 100) | 100 (91.7 to 100) |
| Week 116 | 100 (79.1 to 100) | 96.9 (82.0 to 99.8) | 98.9 (88.2 to 99.9) |
| Week 128 | 100 (78.1 to 100) | 100 (86.3 to 100) | 100 (90.9 to 100) |
| Week 140 | 100 (78.1 to 100) | 100 (87.0 to 100) | 100 (91.3 to 100) |
| Week 156 | 94.7 (71.9 to 99.7) | 100 (87.0 to 100) | 98.1 (88.4 to 99.9) |
| Week 180 | 94.7 (71.9 to 99.7) | 97.0 (82.5 to 99.8) | 96.2 (85.7 to 99.3) |
| Week 208 | 100 (78.1 to 100) | 100 (86.3 to 100) | 100 (90.9 to 100) |
| Week 232 | 94.1 (69.2 to 99.7) | 100 (84.5 to 100) | 97.7 (86.5 to 99.9) |
| Week 260 | 92.9 (64.2 to 99.6) | 96.2 (78.4 to 99.8) | 95.0 (81.8 to 99.1) |
| Week 284 | 100 (73.2 to 100) | 95.7 (76.0 to 99.8) | 97.3 (84.2 to 99.9) |
| Week 308 | 100 (69.9 to 100) | 100 (77.1 to 100) | 100 (85.4 to 100) |
| Week 312 | 90.0 (54.1 to 99.5) | 100 (69.9 to 100) | 95.5 (75.1 to 99.8) |
The JIA ACR response criteria consisted of 6 core criteria: * Physician global assessment of disease activity on a 0-100 mm VAS (0=very good and 100=very poor). * Parent's or patients' global assessment of overall well-being on a 0-100 mm VAS (0=very well and 100=very poor). * Functional ability (CHAQ): 30 questions across 8 domains assessing the child's functional abilities. The total score was calculated as the average of the scores for each domain (0 \[no disability\] to 3 \[very severe disability\]). * Number of joints with active arthritis (as per ACR definition), ranging from 0 to 73. * Number of joints with limited range of motion, ranging from 0 to 69. * Index of inflammation: CRP levels The JIA ACR 50 responses were achieved if 3 of any 6 core set variables improved by at least 50% from baseline of the core study, and no more than 1 variable worsening \> 30%
| Percentage of participants | Group 1- Secukinumab 75 mg | Group 2 - Secukinumab 150 mg | Total Secukinumab Dose |
|---|---|---|---|
| Week 104 | 94.7 (71.9 to 99.7) | 94.3 (79.5 to 99.0) | 94.4 (83.7 to 98.6) |
| Week 116 | 100 (79.1 to 100) | 93.8 (77.8 to 98.9) | 96.1 (85.4 to 99.3) |
| Week 128 | 94.4 (74.2 to 98.7) | 93.5 (77.2 to 98.9) | 93.9 (82.1 to 98.4) |
| Week 140 | 100 (78.1 to 100) | 90.9 (74.5 to 97.6) | 94.1 (82.8 to 98.5) |
| Week 156 | 94.7 (71.9 to 99.7) | 87.9 (70.9 to 96.0) | 90.4 (78.2 to 96.4) |
| Week 180 | 94.7 (71.9 to 99.7) | 93.9 (78.4 to 98.9) | 94.2 (83.1 to 98.5) |
| Week 208 | 100 (78.1 to 100) | 90.3 (73.1 to 97.5) | 93.9 (82.1 to 98.4) |
| Week 232 | 94.1 (69.2 to 99.7) | 96.3 (79.1 to 99.8) | 95.5 (83.3 to 99.2) |
| Week 260 | 92.9 (64.2 to 99.6) | 96.2 (78.4 to 99.8) | 95.0 (81.8 to 99.1) |
| Week 284 | 100 (73.2 to 100) | 95.7 (76.0 to 99.8) | 97.3 (84.2 to 99.9) |
| Week 308 | 100 (69.9 to 100) | 100 (77.1 to 100) | 100 (85.4 to 100) |
| Week 312 | 90.0 (54.1 to 99.5) | 100 (69.9 to 100) | 95.5 (75.1 to 99.8) |
The JIA ACR response criteria consisted of 6 core criteria: * Physician global assessment of disease activity on a 0-100 mm VAS (0=very good and 100=very poor). * Parent's or patients' global assessment of overall well-being on a 0-100 mm VAS (0=very well and 100=very poor). * Functional ability (CHAQ): 30 questions across 8 domains assessing the child's functional abilities. The total score was calculated as the average of the scores for each domain (0 \[no disability\] to 3 \[very severe disability\]). * Number of joints with active arthritis (as per ACR definition), ranging from 0 to 73. * Number of joints with limited range of motion, ranging from 0 to 69. * Index of inflammation: CRP levels The JIA ACR 70 responses were achieved if 3 of any 6 core set variables improved by at least 70%, from baseline of the core study, and no more than 1 variable worsening \> 30%
| Percentage of participants | Group 1- Secukinumab 75 mg | Group 2 - Secukinumab 150 mg | Total Secukinumab Dose |
|---|---|---|---|
| Week 104 | 94.7 (71.9 to 99.7) | 82.9 (65.7 to 92.8) | 87.0 (74.5 to 94.2) |
| Week 116 | 94.7 (71.9 to 99.7) | 90.6 (73.8 to 97.5) | 92.2 (80.3 to 97.5) |
| Week 128 | 94.4 (70.6 to 99.7) | 90.3 (73.1 to 97.5) | 91.8 (79.5 to 97.4) |
| Week 140 | 88.9 (63.9 to 98.1) | 84.8 (67.3 to 94.3) | 86.3 (73.1 to 93.8) |
| Week 156 | 94.7 (71.9 to 99.7) | 84.8 (67.3 to 94.3) | 88.5 (75.9 to 95.2) |
| Week 180 | 89.5 (65.5 to 98.2) | 81.8 (63.9 to 92.4) | 84.6 (71.4 to 92.7) |
| Week 208 | 94.4 (70.6 to 99.7) | 90.3 (73.1 to 97.5) | 91.8 (79.5 to 97.4) |
| Week 232 | 88.2 (62.3 to 97.9) | 85.2 (65.4 to 95.1) | 86.4 (72.0 to 94.3) |
| Week 260 | 92.9 (64.2 to 99.6) | 96.2 (78.4 to 99.8) | 95.0 (81.8 to 99.1) |
| Week 284 | 100 (73.2 to 100) | 95.7 (76.0 to 99.8) | 97.3 (84.2 to 99.9) |
| Week 308 | 100 (69.9 to 100) | 100 (77.1 to 100) | 100 (85.4 to 100) |
| Week 312 | 90.0 (54.1 to 99.5) | 83.3 (50.9 to 97.1) | 86.4 (64.0 to 96.4) |
The JIA ACR response criteria consisted of 6 core criteria: * Physician global assessment of disease activity on a 0-100 mm VAS (0=very good and 100=very poor). * Parent's or patients' global assessment of overall well-being on a 0-100 mm VAS (0=very well and 100=very poor). * Functional ability (CHAQ): 30 questions across 8 domains assessing the child's functional abilities. The total score was calculated as the average of the scores for each domain (0 \[no disability\] to 3 \[very severe disability\]). * Number of joints with active arthritis (as per ACR definition), ranging from 0 to 73. * Number of joints with limited range of motion, ranging from 0 to 69. * Index of inflammation: CRP levels The JIA ACR 90 responses were achieved if 3 of any 6 core set variables improved by at least 90% from baseline of the core study, and no more than 1 variable worsening \> 30%
| Percentage of participants | Group 1- Secukinumab 75 mg | Group 2 - Secukinumab 150 mg | Total Secukinumab Dose |
|---|---|---|---|
| Week 104 | 84.2 (59.5 to 95.8) | 74.3 (56.4 to 86.9) | 77.8 (64.1 to 87.5) |
| Week 116 | 73.7 (48.6 to 89.9) | 75.0 (56.2 to 87.9) | 74.5 (60.1 to 85.2) |
| Week 128 | 83.3 (57.7 to 95.6) | 77.4 (58.5 to 89.7) | 79.6 (65.2 to 89.3) |
| Week 140 | 83.3 (57.7 to 95.6) | 72.7 (54.2 to 86.1) | 76.5 (62.2 to 86.8) |
| Week 156 | 73.7 (48.6 to 89.9) | 75.8 (57.4 to 88.3) | 75.0 (60.8 to 85.5) |
| Week 180 | 84.2 (59.5 to 95.8) | 69.7 (51.1 to 83.8) | 75.0 (60.8 to 85.5) |
| Week 208 | 77.8 (51.9 to 92.6) | 71.0 (51.8 to 85.1) | 73.5 (58.7 to 84.6) |
| Week 232 | 76.5 (49.8 to 92.2) | 81.5 (61.3 to 93.0) | 79.5 (64.2 to 89.7) |
| Week 260 | 71.4 (42.0 to 90.4) | 84.6 (64.3 to 95.0) | 80.0 (63.9 to 90.4) |
| Week 284 | 85.7 (56.2 to 97.5) | 95.7 (76.0 to 99.8) | 91.9 (77.0 to 97.9) |
| Week 308 | 91.7 (59.8 to 99.6) | 88.2 (62.3 to 97.9) | 89.7 (71.5 to 97.3) |
| Week 312 | 80.0 (44.2 to 96.5) | 83.3 (50.9 to 97.1) | 81.8 (59.0 to 94.0) |
The JIA ACR response criteria consisted of 6 core criteria: * Physician global assessment of disease activity on a 0-100 mm VAS (0=very good and 100=very poor). * Parent's or patients' global assessment of overall well-being on a 0-100 mm VAS (0=very well and 100=very poor). * Functional ability (CHAQ): 30 questions across 8 domains assessing the child's functional abilities. The total score was calculated as the average of the scores for each domain (0 \[no disability\] to 3 \[very severe disability\]). * Number of joints with active arthritis (as per ACR definition), ranging from 0 to 73. * Number of joints with limited range of motion, ranging from 0 to 69. * Index of inflammation: CRP levels The JIA ACR 100 responses were achieved if 3 of any 6 core set variables improved with 100% from baseline of the core study, and no more than 1 variable worsening \> 30%
| Percentage of participants | Group 1- Secukinumab 75 mg | Group 2 - Secukinumab 150 mg | Total Secukinumab Dose |
|---|---|---|---|
| Week 104 | 63.2 (38.6 to 82.8) | 57.1 (39.5 to 73.2) | 59.3 (45.1 to 72.1) |
| Week 116 | 63.2 (38.6 to 82.8) | 62.5 (43.7 to 78.3) | 62.7 (48.1 to 75.5) |
| Week 128 | 66.7 (41.2 to 85.6) | 54.8 (36.3 to 72.2) | 59.2 (44.3 to 72.7) |
| Week 140 | 66.7 (41.2 to 85.6) | 57.6 (39.4 to 74.0) | 60.8 (46.1 to 73.8) |
| Week 156 | 63.2 (38.6 to 82.8) | 60.6 (42.2 to 76.6) | 61.5 (47.0 to 74.4) |
| Week 180 | 57.9 (34.0 to 78.9) | 54.5 (36.6 to 71.5) | 55.8 (41.4 to 69.3) |
| Week 208 | 72.2 (46.4 to 89.3) | 58.1 (39.3 to 74.9) | 63.3 (48.3 to 76.2) |
| Week 232 | 58.8 (33.5 to 80.6) | 63.0 (42.5 to 79.9) | 61.4 (45.5 to 75.3) |
| Week 260 | 71.4 (42.0 to 90.4) | 65.4 (44.4 to 82.1) | 67.5 (50.8 to 80.9) |
| Week 284 | 78.6 (48.8 to 94.3) | 78.3 (55.8 to 91.7) | 78.4 (61.3 to 89.6) |
| Week 308 | 91.7 (59.8 to 99.6) | 76.5 (49.8 to 92.2) | 82.8 (63.5 to 93.5) |
| Week 312 | 80.0 (44.2 to 96.5) | 75.0 (42.8 to 93.3) | 77.3 (54.2 to 91.3) |
Inactive disease status was confirmed in a patient when all the following conditions were met: * No joints with active arthritis * No uveitis * CRP value within normal limits for the laboratory where tested or, if elevated, not attributable to JIA * Physician's global assessment of disease activity score ≤ 10mm * Duration of morning stiffness attributable to JIA lasting ≥15 minutes.
| Percentage of Participants | Group 1- Secukinumab 75 mg | Group 2 - Secukinumab 150 mg | Total Secukinumab Dose |
|---|---|---|---|
| Week 104 | 63.2 (38.6 to 82.8) | 65.7 (47.7 to 80.3) | 64.8 (50.6 to 77.0) |
| Week 116 | 68.4 (43.5 to 86.4) | 71.9 (53.0 to 85.6) | 70.6 (56.0 to 82.1) |
| Week 128 | 66.7 (41.2 to 85.6) | 64.5 (45.4 to 80.2) | 65.3 (50.3 to 77.9) |
| Week 140 | 72.2 (46.4 to 89.3) | 63.6 (45.1 to 79.0) | 66.7 (52.0 to 77.9) |
| Week 156 | 68.4 (43.5 to 86.4) | 72.7 (54.2 to 86.1) | 71.2 (56.7 to 82.5) |
| Week 180 | 68.4 (43.5 to 86.4) | 54.5 (36.6 to 71.5) | 59.6 (45.1 to 72.7) |
| Week 208 | 61.1 (36.1 to 81.7) | 67.7 (48.5 to 82.7) | 65.3 (50.3 to 77.9) |
| Week 232 | 70.6 (44.0 to 88.6) | 66.7 (46.0 to 82.8) | 68.2 (52.3 to 80.9) |
| Week 260 | 71.4 (42.0 to 90.4) | 65.4 (44.4 to 82.1) | 67.5 (50.8 to 80.9) |
| Week 284 | 78.6 (48.8 to 94.3) | 78.3 (55.8 to 91.7) | 78.4 (61.3 to 89.6) |
| Week 308 | 83.3 (50.9 to 97.1) | 82.4 (55.8 to 95.3) | 82.8 (63.5 to 93.5) |
| Week 312 | 70.0 (35.4 to 91.9) | 75.0 (42.8 to 93.3) | 72.7 (49.6 to 88.4) |
The JIA ACR response criteria consisted of 6 core criteria, one of which was the physician global assessment of disease activity. this assessment was conducted using a 100 mm VAS score, where 0 represented the best disease activity and 100 the worst. The change from baseline of the core study of the physician global assessment of disease activity was measured, with a negative change indicating improvement.
| Score on a Scale | Group 1- Secukinumab 75 mg | Group 2 - Secukinumab 150 mg | Total Secukinumab Dose |
|---|---|---|---|
| Week 104 | -40.0 ± 18.39 | -42.2 ± 20.43 | -41.4 ± 19.59 |
| Week 116 | -40.3 ± 18.42 | -41.1 ± 20.35 | -40.8 ± 19.46 |
| Week 128 | -40.4 ± 18.55 | -41.9 ± 21.33 | -41.3 ± 20.17 |
| Week 140 | -39.0 ± 16.75 | -42.4 ± 19.18 | -41.2 ± 18.26 |
| Week 156 | -39.7 ± 17.09 | -40.8 ± 20.72 | -40.4 ± 19.50 |
| Week 180 | -38.5 ± 18.20 | -38.9 ± 21.71 | -38.8 ± 20.31 |
| Week 208 | -39.0 ± 17.06 | -41.8 ± 19.45 | -40.8 ± 18.48 |
| Week 232 | -38.4 ± 18.20 | -42.9 ± 20.86 | -41.1 ± 19.78 |
| Week 260 | -37.6 ± 28.75 | -45.4 ± 20.74 | -42.7 ± 23.78 |
| Week 284 | -43.6 ± 18.96 | -42.8 ± 20.53 | -43.1 ± 19.68 |
| Week 308 | -43.8 ± 18.76 | -40.3 ± 20.51 | -41.7 ± 19.53 |
| Week 312 | -44.2 ± 26.58 | -47.4 ± 22.05 | -46.0 ± 23.67 |
The JIA ACR response criteria included six core components, one of which was the parent's or patients' global assessment of overall well-being. This assessment was conducted using a 100 mm VAS score, where 0 represented "very well" and 100 "very poor". The change from baseline of the core study in the parent's or patients' global assessment of overall well-being was measured, with a negative change indicating improvement
| Score on a Scale | Group 1- Secukinumab 75 mg | Group 2 - Secukinumab 150 mg | Total Secukinumab Dose |
|---|---|---|---|
| Week 104 | -47.1 ± 25.90 | -38.6 ± 27.74 | -41.6 ± 27.17 |
| Week 116 | -45.4 ± 25.70 | -37.7 ± 26.39 | -40.5 ± 26.15 |
| Week 128 | -46.8 ± 25.02 | -39.1 ± 26.69 | -41.8 ± 26.11 |
| Week 140 | -41.1 ± 27.57 | -38.7 ± 27.06 | -38.7 ± 27.06 |
| Week 156 | -46.1 ± 25.41 | -39.2 ± 27.15 | -41.8 ± 26.49 |
| Week 180 | -45.5 ± 27.24 | -39.8 ± 27.48 | -41.9 ± 27.27 |
| Week 208 | -47.6 ± 25.70 | -40.3 ± 28.13 | -43.0 ± 27.23 |
| Week 232 | -39.6 ± 27.23 | -43.4 ± 28.20 | -41.9 ± 27.57 |
| Week 260 | -44.8 ± 34.52 | -42.8 ± 29.31 | -43.5 ± 30.80 |
| Week 284 | -51.6 ± 24.97 | -43.2 ± 31.23 | -46.4 ± 28.96 |
| Week 308 | -49.8 ± 24.23 | -48.5 ± 31.93 | -49.1 ± 28.53 |
| Week 312 | -48.9 ± 28.45 | -53.5 ± 30.31 | -51.4 ± 28.87 |
The JIA ACR response criteria included six core components, one of which was the functional ability, measured by the CHAQ. The CHAQ questionnaire consisted of 30 questions across 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Each domain was scored on a 4-point scale, and the total score was calculated as the average of the scores for each domain. The total score ranged from 0 (no disability) to 3 (very severe disability). The change from baseline of the core study in the CHAQ was measured, with a negative change indicating improvement.
| Score on a Scale | Group 1- Secukinumab 75 mg | Group 2 - Secukinumab 150 mg | Total Secukinumab Dose |
|---|---|---|---|
| Week 104 | -0.599 ± 0.5490 | -0.636 ± 0.5967 | -0.623 ± 0.5754 |
| Week 116 | -0.605 ± 0.5469 | -0.617 ± 0.5811 | -0.613 ± 0.5631 |
| Week 128 | -0.647 ± 0.5196 | -0.685 ± 0.5570 | -0.672 ± 0.5388 |
| Week 140 | -0.590 ± 0.4809 | -0.648 ± 0.5638 | -0.627 ± 0.5318 |
| Week 156 | -0.645 ± 0.5275 | -0.644 ± 0.5763 | -0.644 ± 0.5537 |
| Week 180 | -0.658 ± 0.5541 | -0.625 ± 0.5779 | -0.637 ± 0.5641 |
| Week 208 | -0.667 ± 0.4832 | -0.625 ± 0.5293 | -0.640 ± 0.5082 |
| Week 232 | -0.610 ± 0.5411 | -0.681 ± 0.5825 | -0.653 ± 0.5615 |
| Week 260 | -0.741 ± 0.5035 | -0.649 ± 0.6205 | -0.681 ± 0.5773 |
| Week 284 | -0.777 ± 0.5052 | -0.652 ± 0.6329 | -0.699 ± 0.5837 |
| Week 308 | -0.865 ± 0.4811 | -0.794 ± 0.6311 | -0.823 ± 0.5655 |
| Week 312 | -0.888 ± 0.5050 | -1.000 ± 0.6077 | -0.949 ± 0.5532 |
The JIA ACR response criteria included six core components, one of which was the number of joints with active arthritis. This was determined using the ACR definition, which identifies active arthritis as any joint with swelling or, in the absence of swelling, limitation of motion accompanied by either pain on motion or tenderness not due to deformity. The active joint count ranged from 0 to 73. The change from baseline of the core study in the number of active joints was measured, with a negative change indicating improvement.
| Joints | Group 1- Secukinumab 75 mg | Group 2 - Secukinumab 150 mg | Total Secukinumab Dose |
|---|---|---|---|
| Week 104 | -8.4 ± 11.03 | -6.9 ± 5.26 | -7.4 ± 7.72 |
| Week 116 | -8.4 ± 11.48 | -6.6 ± 4.50 | -7.3 ± 7.79 |
| Week 128 | -8.7 ± 11.81 | -7.3 ± 5.35 | -7.8 ± 8.24 |
| Week 140 | -8.4 ± 11.81 | -7.0 ± 5.44 | -7.5 ± 8.17 |
| Week 156 | -8.1 ± 9.77 | -7.1 ± 5.61 | -7.5 ± 7.32 |
| Week 180 | -8.3 ± 11.66 | -7.0 ± 5.69 | -7.5 ± 8.29 |
| Week 208 | -7.0 ± 6.12 | -6.7 ± 5.38 | -6.8 ± 5.60 |
| Week 232 | -7.4 ± 8.48 | -7.0 ± 5.68 | -7.1 ± 6.80 |
| Week 260 | -7.9 ± 10.14 | -7.5 ± 5.57 | -7.7 ± 7.36 |
| Week 284 | -8.4 ± 11.61 | -7.0 ± 5.57 | -7.5 ± 8.25 |
| Week 308 | -8.0 ± 9.70 | -6.5 ± 4.52 | -7.1 ± 7.01 |
| Week 312 | -8.9 ± 11.59 | -7.5 ± 5.14 | -8.1 ± 8.48 |
The JIA ACR response criteria included six core components, one of which was the number of joints with limited range of motion. A total of 69 joints were assessed for limitation of motion. The change from baseline of the core study in the number of joints with limited range of motion was measured, with a negative change indicating improvement.
| Joints | Group 1- Secukinumab 75 mg | Group 2 - Secukinumab 150 mg | Total Secukinumab Dose |
|---|---|---|---|
| Week 104 | -5.5 ± 6.20 | -5.3 ± 4.23 | -5.4 ± 4.96 |
| Week 116 | -5.4 ± 6.24 | -5.7 ± 4.19 | -5.6 ± 4.99 |
| Week 128 | -5.5 ± 6.41 | -6.0 ± 4.60 | -5.8 ± 5.28 |
| Week 140 | -5.7 ± 6.31 | -6.0 ± 4.99 | -5.9 ± 5.43 |
| Week 156 | -5.2 ± 5.68 | -4.3 ± 8.19 | -4.6 ± 7.32 |
| Week 180 | -5.3 ± 6.37 | -5.5 ± 4.83 | -5.4 ± 5.38 |
| Week 208 | -5.1 ± 5.61 | -5.3 ± 3.92 | -5.2 ± 4.56 |
| Week 232 | -4.5 ± 5.42 | -5.6 ± 3.93 | -5.2 ± 4.53 |
| Week 260 | -5.2 ± 6.47 | -5.9 ± 3.93 | -5.7 ± 4.90 |
| Week 284 | -5.1 ± 5.72 | -6.0 ± 3.88 | -5.7 ± 4.61 |
| Week 308 | -5.2 ± 5.46 | -5.8 ± 3.05 | -5.5 ± 4.14 |
| Week 312 | -5.3 ± 6.77 | -6.3 ± 3.62 | -5.8 ± 5.17 |
The JIA ACR response criteria included six core components, one of which was CRP levels, an inflammation biomarker. Serum concentrations of CRP were determined, and the change from baseline of the core study was assessed, with negative changes indicating improvement.
| milligram (mg) / liter (L) | Group 1- Secukinumab 75 mg | Group 2 - Secukinumab 150 mg | Total Secukinumab Dose |
|---|---|---|---|
| Week 104 | -15.238 ± 38.0680 | -19.788 ± 36.2920 | -18.187 ± 36.6322 |
| Week 116 | -11.201 ± 40.1619 | -21.795 ± 37.5991 | -17.848 ± 38.5218 |
| Week 128 | -15.027 ± 40.3989 | -21.446 ± 38.2870 | -19.088 ± 38.7812 |
| Week 140 | -15.867 ± 36.7306 | -21.211 ± 37.0123 | -19.325 ± 36.6347 |
| Week 156 | -13.622 ± 34.4677 | -21.325 ± 37.3081 | -18.510 ± 36.1480 |
| Week 180 | -16.131 ± 38.0479 | -20.788 ± 36.9842 | -19.086 ± 37.0716 |
| Week 208 | -16.907 ± 40.1651 | -20.694 ± 38.1014 | -19.303 ± 38.4978 |
| Week 232 | -15.015 ± 41.4765 | -20.365 ± 38.9746 | -18.298 ± 39.5668 |
| Week 260 | -18.746 ± 48.0621 | -20.715 ± 42.7106 | -20.026 ± 44.0482 |
| Week 284 | -19.974 ± 47.7822 | -15.530 ± 59.2045 | -17.212 ± 54.5096 |
| Week 308 | -21.052 ± 53.0822 | -21.458 ± 47.6825 | -21.290 ± 49.0532 |
| Week 312 | -25.915 ± 55.0448 | -27.892 ± 53.5661 | -26.993 ± 52.9390 |
The JADAS-27 was used for assessment of disease activity, and it included 4 measures: * Physician global assessment of disease activity (VAS range: 0 to 10; where 0=very good and 100=very poor) * Parent/participant global assessment of well-being (VAS range: 0 to 10; 0=very well and 100=very poor) * Count of joints with active disease (range: 0 to 27; where 0= no disease activity and 27= maximum disease activity) * Index of inflammation determined by CRP concentration, calculated as: (CRP (mg/l) -10)/10. Before calculation, CRP values \<10 mg/l were converted to 10 and CRP values \>110 mg/l were converted to 110. The normalized scale ranged from 0 to 10; where 0= no disease activity and 10= maximum disease activity. JADAS-27 score was calculated as the sum of the score of its 4 components, ranging from 0 to 57 where 0= no disease activity and 57= maximum disease activity. The change from baseline of the core study was assessed. A negative change from baseline indicated improvement.
| Score on a Scale | Group 1- Secukinumab 75 mg | Group 2 - Secukinumab 150 mg | Total Secukinumab Dose |
|---|---|---|---|
| Week 104 | -14.436 ± 7.2274 | -13.731 ± 7.4131 | -13.979 ± 7.2876 |
| Week 116 | -13.984 ± 7.9693 | -13.632 ± 7.0546 | -13.763 ± 7.3314 |
| Week 128 | -14.478 ± 7.7217 | -14.277 ± 7.3964 | -14.348 ± 7.4314 |
| Week 140 | -14.050 ± 7.6609 | -14.104 ± 7.3246 | -14.085 ± 7.3683 |
| Week 156 | -14.027 ± 6.1256 | -14.158 ± 7.4052 | -14.111 ± 6.9032 |
| Week 180 | -14.235 ± 7.6622 | -13.737 ± 7.5190 | -13.919 ± 7.5002 |
| Week 208 | -13.501 ± 5.7531 | -13.869 ± 7.3790 | -13.734 ± 6.7665 |
| Week 232 | -13.064 ± 6.3732 | -14.669 ± 7.6410 | -14.049 ± 7.1443 |
| Week 260 | -13.454 ± 8.9326 | -15.096 ± 7.9790 | -14.521 ± 8.2484 |
| Week 284 | -15.358 ± 7.3767 | -14.445 ± 8.4302 | -14.791 ± 7.9550 |
| Week 308 | -14.437 ± 6.4218 | -14.647 ± 8.3114 | -14.560 ± 7.4623 |
| Week 312 | -15.310 ± 8.3332 | -17.122 ± 8.2219 | -16.298 ± 8.1255 |
The JADAS-27 was used for assessment of disease activity, and it included 4 measures: * Physician global assessment of disease activity (VAS range: 0 to 10; where 0=very good and 100=very poor) * Parent/participant global assessment of well-being (VAS range: 0 to 10; 0=very well and 100=very poor) * Count of joints with active disease (range: 0 to 71; where 0= no disease activity and 71= maximum disease activity) * Index of inflammation determined by CRP concentration, calculated as: (CRP (mg/l) -10)/10. Before calculation, CRP values \<10 mg/l were converted to 10 and CRP values \>110 mg/l were converted to 110. The normalized scale ranged from 0 to 10; where 0= no disease activity and 10= maximum disease activity. JADAS-27 score was calculated as the sum of the score of its 4 components, ranging from 0 to 101 where 0= no disease activity and 101= maximum disease activity. The change from baseline of the core study was assessed. A negative change from baseline indicated improvement.
| Score on a Scale | Group 1- Secukinumab 75 mg | Group 2 - Secukinumab 150 mg | Total Secukinumab Dose |
|---|---|---|---|
| Week 104 | -17.962 ± 13.2770 | -16.503 ± 9.0939 | -17.016 ± 10.6497 |
| Week 116 | -17.510 ± 14.0289 | -16.226 ± 8.2331 | -16.704 ± 10.6429 |
| Week 128 | -18.595 ± 14.2989 | -17.083 ± 9.1148 | -17.619 ± 11.0980 |
| Week 140 | -17.384 ± 13.8172 | -16.861 ± 9.0858 | -17.046 ± 10.8540 |
| Week 156 | -17.448 ± 11.6294 | -16.855 ± 9.1102 | -17.072 ± 9.9946 |
| Week 180 | -17.709 ± 13.9552 | -16.556 ± 9.4998 | -16.977 ± 11.2105 |
| Week 208 | -16.723 ± 8.8183 | -16.675 ± 9.0536 | -16.693 ± 8.8753 |
| Week 232 | -16.005 ± 10.7335 | -17.262 ± 9.3685 | -16.776 ± 9.8143 |
| Week 260 | -17.239 ± 13.8602 | -18.019 ± 9.7594 | -17.746 ± 11.1907 |
| Week 284 | -19.144 ± 13.7107 | -17.141 ± 10.3338 | -17.899 ± 11.5806 |
| Week 308 | -18.520 ± 12.0126 | -17.000 ± 9.1449 | -17.629 ± 10.2499 |
| Week 312 | -19.810 ± 14.3124 | -19.622 ± 9.0748 | -19.707 ± 11.4427 |
The following 16 entheseal sites were assessed for the presence or absence of tenderness (enthesitis) on each side of the body: * Anterior Entheses: Greater trochanter of the Femur; Medial condyle of the femur; Lateral condyle of the femur * Posterior Entheses: Greater tuberosity of humerus; medial epicondyle of humerus; lateral epicondyle of humerus, Achilles tendon; and calcaneal insertion of the plantar fascia. Tenderness on examination was recorded as either present (1) or absent (0) for each of the 16 sites, The total enthesitis count ranged from 0 to 16. The change from baseline of the core study was assessed. A negative change from baseline indicated improvement
| Enthesitis count | Group 1- Secukinumab 75 mg | Group 2 - Secukinumab 150 mg | Total Secukinumab Dose |
|---|---|---|---|
| Week 104 | -2.5 ± 2.57 | -2.3 ± 2.30 | -2.4 ± 2.37 |
| Week 116 | -2.4 ± 2.36 | -2.3 ± 2.50 | -2.4 ± 2.42 |
| Week 128 | -2.4 ± 2.43 | -2.3 ± 1.97 | -2.3 ± 2.13 |
| Week 140 | -2.5 ± 2.36 | -2.7 ± 2.43 | -2.6 ± 2.38 |
| Week 156 | -2.7 ± 3.03 | -2.5 ± 2.36 | -2.2 ± 2.62 |
| Week 180 | -2.6 ± 2.59 | -2.5 ± 2.54 | -2.5 ± 2.53 |
| Week 208 | -2.4 ± 2.81 | -2.3 ± 2.56 | 2.53 ± 2.63 |
| Week 232 | -2.5 ± 2.85 | -2.0 ± 2.28 | -2.2 ± 2.49 |
| Week 260 | -2.5 ± 3.54 | -2.0 ± 1.36 | -2.2 ± 2.37 |
| Week 284 | -2.9 ± 3.05 | -2.0 ± 1.52 | -2.4 ± 2.21 |
| Week 308 | -3.2 ± 3.07 | -2.1 ± 1.25 | -2.5 ± 2.21 |
| Week 312 | -2.5 ± 2.32 | -2.1 ± 1.44 | -2.3 ± 1.86 |
The dactylitis count was the number of fingers and toes presenting with swelling and inflammation. Swelling and inflammation on examination was recorded as either present (1) or absent (0) for each of the 20 sites, The total dactylitis count ranged from 0 to 20. The change from baseline of the core study was assessed. A negative change from baseline indicated improvement
| Dactylitis count | Group 1- Secukinumab 75 mg | Group 2 - Secukinumab 150 mg | Total Secukinumab Dose |
|---|---|---|---|
| Week 104 | -1.3 ± 1.94 | -0.4 ± 1.97 | -0.7 ± 1.99 |
| Week 116 | -1.5 ± 2.04 | -0.5 ± 2.05 | -0.9 ± 2.08 |
| Week 128 | -1.8 ± 2.39 | -0.5 ± 2.23 | -0.9 ± 2.35 |
| Week 140 | -1.6 ± 2.42 | -0.6 ± 2.09 | -1.0 ± 2.24 |
| Week 156 | -1.6 ± 2.23 | -0.7 ± 2.07 | -1.0 ± 2.15 |
| Week 180 | -1.8 ± 2.41 | 0.0 ± 4.15 | -0.6 ± 3.71 |
| Week 208 | -1.6 ± 2.42 | -0.3 ± 0.87 | -0.8 ± 1.70 |
| Week 232 | -1.5 ± 2.42 | -0.4 ± 0.88 | -0.8 ± 1.70 |
| Week 260 | -1.2 ± 2.04 | -0.3 ± 0.84 | -0.6 ± 1.43 |
| Week 284 | -1.2 ± 2.13 | -0.3 ± 0.95 | -0.6 ± 1.52 |
| Week 308 | -0.9 ± 1.70 | 0.1 ± 0.56 | -0.3 ± 1.22 |
| Week 312 | -1.1 ± 1.83 | -0.2 ± 0.39 | -0.6 ± 1.29 |
Serum concentration of secukinumab over time. Blood samples for pharmacokinetics were taken pre-dose at the scheduled time points.
| microgram (ug)/milliliter (mL) | Group 1- Secukinumab 75 mg | Group 2 - Secukinumab 150 mg | Total Secukinumab Dose |
|---|---|---|---|
| Week 128 | 21.4 ± 8.57 | 26.4 ± 9.78 | 24.8 ± 9.58 |
| Week 156 | 20.8 ± 8.76 | 26.6 ± 11.6 | 24.3 ± 10.8 |
| Week 180 | 21.0 ± 10.4 | 25.2 ± 9.28 | 23.7 ± 9.75 |
| Week 208 | 20.5 ± 6.82 | 26.7 ± 11.4 | 24.3 ± 10.2 |
| Week 232 | 19.7 ± 7.06 | 24.2 ± 11.6 | 22.5 ± 10.2 |
| Week 260 | 16.0 ± 6.94 | 25.4 ± 8.99 | 21.5 ± 9.32 |
| Week 284 | 13.5 ± 7.99 | 27.5 ± 7.48 | 21.7 ± 10.3 |
| Week 308 | 12.5 ± 5.31 | 27.5 ± 14.7 | 18.8 ± 12.4 |
| Week 312 | 14.6 ± 4.79 | 25.4 ± 18.5 | 19.5 ± 13.4 |
Number of participants with treatment-emergent Anti-Drug Antibodies (ADAs) of secukinumab. Blood samples were collected for immunogenicity (anti-AIN457 antibodies) assessments.
| Participants | Group 1- Secukinumab 75 mg | Group 2 - Secukinumab 150 mg | Total Secukinumab Dose |
|---|---|---|---|
| Number of Participants With Treatment-emergent Anti-Drug Antibodies (ADAs) of Secukinumab | 0 | 6 | 6 |
Collected over From first dose of secukinumab in the extension study up to 84 days after last dose of secukinumab, assessed up to approximately 4 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Any Secukinumab 75 mg | 0/19 (0%) | 0/19 (0%) | 15/19 (78.9%) |
| Any Secukinumab 150 mg | 0/43 (0%) | 4/43 (9.3%) | 28/43 (65.1%) |
| Any Secukinumab 300 mg | 0/16 (0%) | 0/16 (0%) | 11/16 (68.8%) |
| Any Secukinumab | 0/54 (0%) | 4/54 (7.4%) | 43/54 (79.6%) |
| Event | Any Secukinumab 75 mg | Any Secukinumab 150 mg | Any Secukinumab 300 mg | Any Secukinumab |
|---|---|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 0/19 | 1/43 | 0/16 | 1/54 |
| Acute sinusitisInfections and infestations | 0/19 | 1/43 | 0/16 | 1/54 |
| ConcussionInjury, poisoning and procedural complications | 0/19 | 1/43 | 0/16 | 1/54 |
| Head injuryInjury, poisoning and procedural complications | 0/19 | 1/43 | 0/16 | 1/54 |
| Subdural haematomaInjury, poisoning and procedural complications | 0/19 | 1/43 | 0/16 | 1/54 |
| Cerebral haemorrhageNervous system disorders | 0/19 | 1/43 | 0/16 | 1/54 |
| Subarachnoid haemorrhageNervous system disorders | 0/19 | 1/43 | 0/16 | 1/54 |
| NephrolithiasisRenal and urinary disorders | 0/19 | 1/43 | 0/16 | 1/54 |
| Urethral haemorrhageRenal and urinary disorders | 0/19 | 1/43 | 0/16 | 1/54 |
| Event | Any Secukinumab 75 mg | Any Secukinumab 150 mg | Any Secukinumab 300 mg | Any Secukinumab |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 2/19 | 8/43 | 4/16 | 13/54 |
| COVID-19Infections and infestations | 1/19 | 9/43 | 3/16 | 13/54 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/19 | 7/43 | 3/16 | 11/54 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/19 | 8/43 | 0/16 | 8/54 |
| Abdominal pain upperGastrointestinal disorders | 3/19 | 4/43 | 0/16 | 6/54 |
| DiarrhoeaGastrointestinal disorders | 1/19 | 5/43 | 1/16 | 7/54 |
| Upper respiratory tract infectionInfections and infestations | 2/19 | 5/43 | 0/16 | 7/54 |
| AstigmatismEye disorders | 0/19 | 0/43 | 2/16 | 2/54 |
| Alanine aminotransferase increasedInvestigations | 0/19 | 1/43 | 2/16 | 3/54 |
| Eosinophil count increasedInvestigations | 0/19 | 0/43 | 2/16 | 2/54 |
Participants who enrolled in the extension study. One patient enrolled with planned treatment secukinumab150 mg discontinued the study before receiving study treatment. This patient was not included in the analysis.
| Age, Continuous(Years) | Group 1- Secukinumab 75 mg | Group 2 - Secukinumab 150 mg | Total |
|---|---|---|---|
| Mean | 9.5 ± 3.49 | 14.1 ± 2.02 | 12.5 ± 3.40 |
| Sex: Female, Male(Participants) | Group 1- Secukinumab 75 mg | Group 2 - Secukinumab 150 mg | Total |
|---|---|---|---|
| Female | 8 | 10 | 18 |
| Male | 11 | 25 | 36 |
| Race/Ethnicity, Customized(Participants) | Group 1- Secukinumab 75 mg | Group 2 - Secukinumab 150 mg | Total |
|---|---|---|---|
| White | 19 | 33 | 52 |
| Other | 0 | 2 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Jun 2019 to primary completion in Nov 2024, 65 months.
Results were first posted in May 2025, 6 months after primary completion.
Of 36 phase 3 interventional studies under Arthritis, Juvenile, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's 65 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab